

1  
2 **Antioxidant and anti-collagenase activity of *Hypericum hircinum* L.**

3  
4  
5 Manuela Mandrone<sup>a</sup>, Beatrice Lorenzi<sup>a</sup>, Alessandro Venditti<sup>b,e</sup>, Laura Guarcini<sup>b,f</sup>, Armandodoriano  
6 Bianco<sup>b</sup>, Cinzia Sanna<sup>c</sup>, Mauro Ballero<sup>c</sup>, Ferruccio Poli<sup>a</sup>, Fabiana Antognoni<sup>d\*</sup>

7  
8  
9 <sup>a</sup> Dipartimento di Farmacia e Biotecnologie, Università di Bologna, via Irnerio, 42 , 40126 Bologna  
10 <sup>b</sup> Dipartimento di Chimica, Sapienza Università di Roma, Piazzale Aldo Moro 5, 00185 Roma,  
11 Italia  
12 <sup>c</sup> Dipartimento di Scienze della Vita e Ambientali, Università di Cagliari, viale Sant' Ignazio, 13,  
13 09123 Cagliari, Italia, Italia  
14 <sup>d</sup> Dipartimento di Scienze per la Qualità della Vita, Università di Bologna, sede di Rimini, Corso  
15 Augusto 237, Rimini, Italia  
16 <sup>e</sup> Dipartimento di Biologia Ambientale, Sapienza Università di Roma, Piazzale Aldo Moro 5, 00185  
17 Roma, Italia  
18 <sup>f</sup> Dipartimento di Chimica e Tecnologie del Farmaco, Sapienza Università di Roma, Piazzale Aldo  
19 Moro 5, 00185 Roma, Italia

20  
21  
22  
23 Corresponding author: Prof. Fabiana Antognoni  
24 Dipartimento di Scienze per la Qualità della Vita – Corso Augusto, 237 -47921 Rimini - Italia  
25 Email : [fabiana.antognoni@unibo.it](mailto:fabiana.antognoni@unibo.it)  
26 Tel . 0039 0541 434623; 0039 051 2091291

27  
28

29 **Abstract**

30

31 *Hypericum hircinum* L. is a shrub traditionally used in some Mediterranean areas as a remedy for  
32 several diseases, mainly linked to the airway apparatus. In this work, an ethanolic extract prepared  
33 from aerial parts of plants collected in Sardinia (Italy), and six fractions isolated by a  
34 chromatographic separation of the extract, were evaluated for their antioxidant activity using three  
35 *in vitro* assays. Based on the ethnobotanical use of the plant and in view of the emerging role that  
36 enzymes belonging to matrix metalloproteinases (MMPs) play in the pathogenesis of some  
37 respiratory diseases, the effect of the crude extract and the fractions on *in vitro* collagenase activity  
38 was also evaluated. Results show that the ethanolic extract and fractions containing quercetin,  
39 chlorogenic acid, and 5,7,3',5'-tetrahydroxyflavanone, a component recently identified in this  
40 species, are endowed with the highest free radical scavenging activity. Conversely, fractions  
41 containing as a main component shikimic acid did not show this property. The crude extract was  
42 able to inhibit *in vitro* collagenase activity with an IC<sub>50</sub> value of 156 µg/mL. A Lineaweaver-Burk  
43 plot, built to obtain the kinetic parameters of the enzymatic reaction, revealed that the inhibitory  
44 mechanism is non-competitive. Single fractions were also evaluated for their inhibitory activity on  
45 collagenase, and fractions mainly containing flavonols and the substituted flavanone showed the  
46 highest inhibitory effect. Thus, *H. hircinum* can be considered a new natural source of molecules  
47 able to inhibit enzymes of the MMP family, which could enter as active ingredients in wrinkle-care  
48 cosmetics.

49

50 **Keywords:** Anti-collagenase activity, *Hypericum hircinum* L., Matrix metalloproteinase inhibition,  
51 Mediterranean Traditional Medicine.

52

53 **Abbreviations:** BA: betulinic acid; CA: chlorogenic acid; HCAs: hydroxycinnamic acids; Q:  
54 quercetin; SA: shikimic acid, THFL: 5,7,3',5'-tetrahydroxyflavanone; THFL-Glc: 5,7,3',5'-  
55 tetrahydroxyflavanone-7-*O*-glucoside.

56

57 **1. Introduction**

58 *Hypericum hircinum* L. is a semi-evergreen shrub belonging to the Hypericaceae family. It is  
59 widely distributed in the Mediterranean area, where it is commonly known as ‘goat St. John’s wort’  
60 and traditionally used as a remedy for several diseases. In Italy, both the decoction and the infusion  
61 are utilized in the treatment of airway diseases; in Sardinian folk medicine, its use is reported in  
62 chronic catarrhal affections and asthma (Atzei, 2003), and in Lucanian folk medicine for treatment  
63 of cough (Pieroni et al., 2004). In Sardinia, *H. hircinum* oil is used to treat skin burns and is  
64 considered effective as antiseptic, while the hydroalcoholic extract is topically used to relieve  
65 rheumatic pains, to treat sciatica, sprains and dislocations, as well as for wound healing (Ballero et  
66 al., 1997).

67 Despite the numerous studies carried out on the species *H. perforatum*, which is well known for  
68 its therapeutic use in the treatment of mild to moderate depression (Butterweck, 2003; Ernst and  
69 Izzo, 2003; Rodriguez-Landa and Contreras, 2003), much less information is available on other  
70 species of this genus. As regards *H. hircinum*, studies have demonstrated antimicrobial and  
71 antifungal activities (Maggi et al., 2010a; Cecchini et al., 2007; Pistelli et al., 2000; Barbagallo and  
72 Chisari, 1987), herbicide potential, (Araniti et al., 2012; Marandino et al., 2011), a selective action  
73 as MAO-A inhibitor (Chimenti et al., 2006) and a protective effect on doxorubicin-induced  
74 cardiotoxicity in rats (Shah et al., 2013). Recently, Esposito et al. (2013) have reported for this  
75 species an inhibitory activity on HIV replication, targeted on both DNA polymerase and  
76 ribonuclease H activities.

77 The phytochemical composition of both the essential oil (Maggi et al., 2010b) and the non-  
78 volatile fraction obtained from different parts of *H. hircinum* subsp. *majus* (Aiton) from the Marche  
79 (Italy), has been investigated (Cecchini et al., 2007; Maggi et al., 2010a; Maggi et al., 2010b).  
80 Essential oils from aerial parts are dominated by sesquiterpene hydrocarbons, while the non-volatile  
81 leaf extract contains chloro-genic acid, quercetin, mangiferin, and biagenin (Pistelli et al., 2000),  
82 but lacks hypericin, one of the most active constituents of *H. perforatum* (Cecchini et al., 2007).

83 Matrix metallo proteinases (MMPs) are a family of transmembrane zinc-containing  
84 endoproteinases, which have been traditionally characterized by their collective ability to degrade,  
85 at neutral pH, all components of the extracellular matrix. They include, among others, collagenases  
86 and gelatinases, the former being metalloproteinases capable of cleaving, besides collagen, other  
87 molecules found in cells, such as aggrecan, elastin, fibronectin, gelatine and laminin (Raffetto and  
88 Khalil, 2008). A plethora of roles has been recently recognized for this class of enzymes; they are  
89 responsible for excessive cartilage degradation, which is considered the most important  
90 pathological event associated with rheumatoid arthritis and osteoarthritis (Elliott and Cawston,  
91 2001) and an excessive degradation of newly formed extracellular matrix (ECM) has been found to  
92 be related to non-healing wounds.(Schultz et al., 2005; Vaalamo et al., 1996) An important role for  
93 MMPs has been reported in the pathological processes associated with chronic obstructive  
94 pulmonary disease (COPD), being responsible for the destruction of alveoli due to the degradation  
95 of elastin in their walls (Belvisi and Bottomley, 2003).

96 In view of these evidences, and based on the ethnobotanical uses of *H. hircinum*, we  
97 hypothesized that matrix protease inhibition may represent one of the mechanisms by which  
98 extracts of this plant exert their beneficial action. Thus, in this work, our attention was focused on  
99 the effect of *H. hircinum* hydro alcoholic extracts on activity of collagenase, an enzymatic target  
100 involved in ECM degradation. Moreover, considering the role that free radicals play in the  
101 pathogenesis of different diseases and in the activation of MMPs (Fu et al., 2001), an evaluation of  
102 the antioxidant potential of these extracts was carried out using different *in vitro* assays in order to  
103 obtain a more comprehensive picture. With the aim of identifying the most active components in  
104 modulating the enzyme activities, a comparison between the crude extracts and fractions obtained  
105 by chromatographic separation and pure standards of the most abundant phytochemical constituents  
106 was also carried out.

107

108

## 109 **2. Material and methods**

### 110 *2.1. Chemicals and instruments*

111 Reagents were purchased from Sigma Aldrich Chemical Company (St. Louis, MO, USA).  
112 Solvents of analytical or HPLC grade were purchased from VWR (Darmstadt, Germany).  
113 Biological assays were performed using a microplate reader Victor X3 Perkin Elmer (Perkin Elmer  
114 Inc., Massachusetts USA) and data analysed by Work Out 2.5 software, or in a Jasco V-530  
115 Spectrophotometer (Jasco Europe, Cremella, Italy).

116 HPLC analyses were carried out on a Jasco system (Jasco Corp., Tokyo, Japan) consisting of  
117 a PU-1580 pump, an LG-1580-02 ternary gradient unit, a DG-1580-53 three-line degasser and a  
118 PDA detector (MD-2018 Plus) linked to an autosampler (AS 2055 Plus).

119 NMR spectra were recorded on Varian Mercury 300 MHz instrument and/or on Bruker  
120 Avance III 400 MHz instruments. operating at 9.4 T at 298° K. Deuterated solvents (CDCl<sub>3</sub>,  
121 CD<sub>3</sub>OD or D<sub>2</sub>O) were used to solubilise the samples; the chemical shift was expressed in ppm from  
122 TMS for spectra spectra in CDCl<sub>3</sub>, the signal of HDO at 4.78 ppm is used as reference for spectra in  
123 D<sub>2</sub>O, the internal solvent signal at 3.31 ppm was used as reference for spectra in CD<sub>3</sub>OD.

124 HR-MS spectra were acquired on a Q-TOF MICRO Spectrometer (Micromass, now Waters,  
125 Manchester, UK) equipped with an ESI source, operating in both negative and positive ion mode.  
126 The flow rate of sample infusion was 10 µL/min, with a minimum of 100 acquisitions per spectrum.  
127 Data were analysed by using the MassLynx software developed by Waters.

### 128 *2.2. Plant material*

129 Aerial parts of *Hypericum hircinum* L. plants at flowering stage were collected in Jerzu  
130 (Sardinia, Italy) in July 2010 and authenticated by C. Sanna. A voucher specimen (Herbarium CAG  
131 232) was deposited in the General Herbarium of the 'Dipartimento di Scienze della Vita e  
132 dell'Ambiente, Macrosezione Botanica e Orto Botanico', University of Cagliari (CAG), Sardinia,  
133 Italy.

134           2.3.    *Preparation of extract and fractions*

135           Plant material was dried at 40°C until constant weight and finely powdered with an electric  
136 grinder. Milled material (400 g) was extracted with 96% ethanol for 24 h and extraction was  
137 repeated three times (3 × 600 mL). The extracts were gathered and filtered, then the ethanol was  
138 evaporated under reduced pressure at 40°C. The resulting water suspension was freeze dried, and  
139 the extract was stored at 4 °C until use. The final yield of the extraction was 9.25% (w/w).

140           The crude ethanolic extract was fractionated by repeated column chromatography (CC) on  
141 silica gel, using different solvent mixtures as eluting solutions: saturated *n*-butanol/water and  
142 chloroform/methanol at different percentages (starting with a 9.5:0.5 ratio and gradually increasing  
143 the polarity during the chromatographic run to 9.0:1.0, 8.0:2.0, 7.0:3.0, 6.0:4.0). The fractionation  
144 was monitored by TLC by using spray reagents for detection (2 N H<sub>2</sub>SO<sub>4</sub>, 3 % aqueous FeCl<sub>3</sub>). Six  
145 fractions (named F1-F6) were obtained, and the identity of the single components was evaluated by  
146 means of spectroscopic methods (NMR, MS) in comparison with literature data, and/or by  
147 comparison with standard compounds available in our laboratory. The main components were the  
148 following: betulinic acid (BA), shikimic acid (SA), chlorogenic acid (CA), quercetin (Q), 5,7,3',5'-  
149 tetrahydroxyflavanone (THFL), and 5,7,3',5'-tetrahydroxyflavanone-7-*O*-glucoside.

150           2.4. *Spectrophotometric and chromatographic analyses*

151           Total polyphenol (TP) and flavonoid concentrations of the extract were determined as  
152 reported by Di Pompo et al. (2014) and expressed as mg Gallic Acid Equivalents (GAE)/mg extract  
153 and mg Rutin Equivalents (RE)/mg extract, respectively.

154           HPLC analysis of the extract was carried out using a C18 column (Luna C18, 5 µm, 100 Å,  
155 4.6 × 150 mm, Phenomenex Italy, Castelmaggiore, Bologna, Italy). CA, Q and SA were identified  
156 according to Brolis et al. (1998). UV detection of CA was performed at 320 nm, SA at 210 nm and  
157 Q at 370 nm. Retention times were 2.5, 13.5 and 23.7 min for SA, CA and Q, respectively.

158 A calibration curve with the appropriate analytical standard at different concentrations (from  
159 0.5 to 500 ppm) was constructed for the quantitative analysis. For Q the following concentrations  
160 were used: 0.5, 1.0, 5.0, 10.0, 20.0, 50.0, 100.0 ppm; for CA and SA 1.0, 5.0, 10.0, 50.0, 100.0,  
161 200.0, 500.0 ppm were used. Peak identity and purity were confirmed by means of the PDA  
162 detector.

### 163 2.5. Antioxidant assays

164 DPPH, ABTS and FRAP-Ferrozine (FZ) tests were performed according to Venditti et al.  
165 (2013). The FRAP-FZ was modified as compared to the original FRAP assay (Benzie and Strain,  
166 1996) with respect to the pH value. In the ABTS and DPPH assays, the ethanolic extract or purified  
167 fractions were tested in a concentration range of 5-20  $\mu\text{g/mL}$ , and Trolox (Tr) or pure standard  
168 compounds (CA, Q, SA) in a concentration range of 5-50  $\mu\text{M}$ . In the FRAP-FZ assay, extract or  
169 purified fractions were tested in a concentration range of 10-100  $\mu\text{g/mL}$  and Tr or pure standard  
170 compounds from 10 to 100  $\mu\text{M}$ . The antioxidant capacity is expressed as  $\text{IC}_{50}$  and TAC values for  
171 extract and fractions, and as  $\text{IC}_{50}$ , TAC and TEAC for pure compounds.

### 172 2.6. Collagenase activity assay

173 Collagenase assay was performed according to Van Wart and Steinbrink (1981) with slight  
174 modifications. Collagenase (E.C. 3.4.24.3) from *Clostridium histolyticum* (type IA, ChC; specific  
175 activity 11.72 U/mg) was purchased from Sigma Aldrich Co (Saint Louis, MO). 20 mU enzyme,  
176 prepared in Tricine buffer (0.05 M, pH 7.5), containing 0.4 M NaCl and 0.01 M  $\text{CaCl}_2$ , were  
177 incubated for 10 min with test samples at different concentrations (from 10 to 300  $\mu\text{g/mL}$ ). The  
178 synthetic substrate N-(3-[2-Furyl]-acryloyl)-Leu-Gly-Pro-Ala (FALGPA), prepared in the same  
179 buffer solution, was added to start the reaction (final concentration 0.8 mM) in a final volume of  
180 125  $\mu\text{L}$ . The change in absorbance was monitored for a time interval of 5 min at 340 nm in the  
181 microplate reader under a constant temperature of 30 °C. The  $\text{IC}_{50}$  value was calculated by  
182 constructing a linear regression curve showing sample concentrations on the x-axis and percentage

183 inhibition on the y-axis. The percentage of inhibition of enzyme activity was calculated by the  
184 following formula:

$$185 \quad \% \text{ Inhibition} = [1 - (\Delta\text{Abs}/\text{min}_{\text{sample}} / \Delta\text{Abs}/\text{min}_{\text{negative control}}) \times 100]$$

186 Water, instead of samples, was used as negative control.  $\Delta\text{Abs}$  values were calculated in the  
187 time interval and referred to 1 min. The positive control was represented by epigallocatechin gallate  
188 (EGCG), a well-known natural collagenase inhibitor (Madhan et al., 2004).

189 A Lineweaver-Burk (L-B) plot was constructed to calculate the kinetic parameters ( $K_m$   
190 expressed in mM and  $V_{\text{max}}$  in  $\mu\text{kat}$ ) of the enzymatic reaction without and with samples at the  $\text{IC}_{50}$   
191 concentration ( $K_{m_{\text{app}}}$  is the apparent  $K_m$  in the presence of the inhibitor). Different FALGPA  
192 concentrations were used from 0.4 to 1 mM; the rate of the enzymatic reaction expressed in  $\mu\text{kat}$   
193 was calculated from  $\Delta\text{Abs}$  0-300 s, considering FALGPA  $\epsilon$  at 345 nm =  $24.7 \text{ M}^{-1} \text{ cm}^{-1}$  and a light  
194 path length of 0.4 cm.

### 195 *2.7. Statistical analysis*

196 All values are expressed as the mean  $\pm$  SD of three independent experiments with samples in  
197 duplicate. Statistical analysis was performed using Graph Pad Prism 4 software (La Jolla, CA) by  
198 One-way Analysis of Variance (ANOVA), considering significant differences at  $P < 0.05$ .  
199  $\text{IC}_{50}$  values were calculated by Regression Analysis using Graph Pad Prism 4 software.

200 TEAC values, defined as the mM concentration of a Tr solution having an activity equivalent  
201 to a 1.0 mM solution of the substance under investigation (Rahman and MacNee, 1996), was  
202 calculated for pure standard compounds. TAC values, calculated for crude extracts and fractions,  
203 are expressed as mmol Tr equivalent/g extract.

204

## 205 **3. Results and discussion**

### 206 *3.1. Chemical composition of H. hircinum extract and fractions*



207 Total polyphenols (TP) and flavonoids detected in the ethanolic extract of the aerial parts of  
208 Sardinian *H. hircinum* samples. TP content was 20% on a dry weight basis, and flavonoids  
209 represent the main polyphenolic component (16.7%). TP content was higher, but of the same order  
210 of magnitude, as that observed by Pilepić and Males (2013) in cultivated populations of the same  
211 species. This difference can be related to the different growing conditions since plants collected in  
212 nature, such as those used in this study, are more exposed to environmental factors able to induce  
213 the production of defense compounds compared to cultivated plants. Moreover, the different  
214 weather conditions may also justify the higher content. Indeed, variations in TP were observed by  
215 these authors also within a same *Hypericum* species in two subsequent harvesting years (Pilepić and  
216 Males, 2013).

217 The phytochemical profile of the same *H. hircinum* extract used in this work has been  
218 reported by Esposito et al. (2013) and results revealed the presence of CA, SA, BA, Q, THFL, and  
219 THFL-Glc, the latter two compounds having been identified in this species for the first time. A  
220 quali-quantitative analysis of the extract by HPLC-DAD revealed that the SA content of the  
221 ethanolic extract was  $112.39 \pm 2.13$  mg/g extract, which, considering the extraction yield,  
222 corresponds to 0.99% on a dry mass basis. This confirms that *Hypericum* spp. represent a good  
223 source of this metabolic intermediate (Bochov et al., 2012). SA content of the ethanolic extract was  
224 107.51 mg/g extract, which corresponds to 0.99 % on a dry mass basis, considering the extraction  
225 yield, confirming that *Hypericum* spp. represents a good source of this metabolic intermediate  
226 (Bochkov et al., 2012). CA was also found in rather high amounts (40 mg/g extract), while Q was  
227 present at much lower levels ( $2.31 \pm 0.30$  mg/g). The amount of CA was about 10 times higher than  
228 that found by Cecchini et al. (2007), in *H. hircinum* plants collected in central Italy, and this may  
229 reflect the variability due to growth and environmental conditions.

230 Based on NMR and MS spectra, the phytochemical composition of the six fractions purified  
231 from the ethanolic extract, was the following: the most lipophilic fraction (F1) contained waxes and  
232 BA, intermediate fractions (F2-F3) contained flavonoid aglycons THFL and Q, and the most

233 hydrophilic ones (F4-F6) contained flavonoid glycosides, HCAs, SA and sugars. F2 and F4 contain  
234 as unique components THFL and its glucoside, respectively, which have been recently identified in  
235 this species (Esposito et al., 2013). F3 contains THFL and Q as main components. The presence of  
236 other constituents, such as BA, CA, SA and HCAs confirmed earlier reports (Chimenti et al., 2006;  
237 Pistelli et al., 2000; Esposito et al., 2013).

### 238 3.2 Antioxidant activity of crude extract, fractions and isolated compounds

239 The antioxidant activity of the *H. hircinum* ethanolic extract and the six fractions was  
240 evaluated by three different *in vitro* tests, all based on the same single electron transfer mechanism.  
241 The IC<sub>50</sub> values of the crude extract obtained by the ABTS and DPPH tests were very similar to  
242 each other (Fig. 1A), and reflect a rather high radical scavenging activity, since they were only twice  
243 or three times higher compared to Tr. (Figures 1-2). The radical scavenging capacity resulting from  
244 the DPPH assay was comparable to the one reported for *H. perforatum* extract (7.5 µg/ml) whereas  
245 the value obtained in the ABTS test was lower than that reported earlier for this species (28.5  
246 µg/ml) (Raghu et al., 2009). The FRAP-FZ test, performed in order to evaluate the reducing  
247 potential of the sample towards the redox couple Fe<sup>3+</sup>/Fe<sup>2+</sup> (Berker et al., 2010), confirmed the  
248 strength of *H. hircinum* extract as antioxidant, since a TAC value of 0.91 was found (Tab. 1). This  
249 value was higher than that obtained by Berker et al. (2010) for *Camellia sinensis* extract, which is  
250 considered a rather powerful antioxidant.

251 A comparison between the antioxidant activity of the ethanolic extract and of the single  
252 fractions (Figs. 1-2) shows that, according to both the DPPH and ABTS assays, F3 and F5 were the  
253 most active fractions, with an activity that was not significantly different from that of the crude  
254 extract (Fig. 1A). Since the main components of these fractions were Q, THFL, CA, and an  
255 unknown flavonol glycoside (Tab. 2), the antioxidant activity of pure compounds Q and CA was  
256 assayed, in order to identify those mainly responsible for this property. Besides these, SA was also  
257 tested, since it was the main component in the ethanolic extract. Q and CA showed a very high  
258 antioxidant ability, which was higher than that of Tr in all tests (Fig. 1B and Table 1).

259 THFL is a constituent of the leaves of *Olea ferruginea* (Aiton) Steud (Hashmi et al., 2014),  
260 and *Blumea balsamifera* (L.) DC. (Nessa et al., 2004), twigs of *Broussonetia papyrifera* (L.) L'Hér.  
261 ex Vent. (Zheng et al., 2008), and of aerial parts of *Thymus quinquecostatus* var. *japonicus* H. Hara  
262 (Lee et al., 2011). A clear antioxidant capacity for this flavanone derivative has been demonstrated,  
263 even though comparatively lower than that exerted by flavones and flavonols (Nessa et al., 2004).  
264 This can explain the higher free radical scavenging activity of F3 (that contained both Q and THFL)  
265 as compared to F2, which mainly contains the flavanone derivative (Fig. 1A). Thus, it is plausible  
266 that the flavonol components, together with derivative flavanones and caffeoylquinic acids, mainly  
267 contributed to the antioxidant capacity of the *H. hircinum* crude extract (Fig.1). Conversely, no  
268 radical scavenging activity was recorded for SA (data not shown), although it was present in rather  
269 high amounts in the ethanolic extract.

### 270 3.3. Anti-collagenase activity of crude extract, fractions, and isolated compounds

271 *H. hircinum* extract was able to inhibit the *in vitro* collagenase activity, with an IC<sub>50</sub> value of  
272 156.0 µg/mL (Fig. 3A). In order to understand which components of the crude extract may account  
273 for the inhibitory effect, single fractions were investigated for their effect on enzyme activity. A  
274 fixed concentration of 60 µg/mL of each fraction was tested, and the percentage of enzymatic  
275 inhibition was compared (Fig. 3B). The inhibitory effect decreased in the order: F2>F3>F5>F6>F4.  
276 IC<sub>50</sub> values were calculated for fractions showing a percentage inhibition of at least 30% at the  
277 tested concentration (Fig. 3B). All tested fractions were able to inhibit collagenase activity largely  
278 than the total extract, and, among them, the most active ones were F2 and F3. These fractions  
279 mainly contained THFL, alone and together with Q, respectively. The effectiveness of flavonols as  
280 collagenase inhibitors has been well documented (Sin and Kim, 2005). These authors, by  
281 comparing various flavonoids for their inhibitory action on collagenase activity, found that  
282 quercetin and kaempferol showed a higher inhibitory effect compared to flavones, isoflavones, and  
283 flavanones, the latter being almost ineffective. Nevertheless, by comparing different structures, they  
284 concluded that the hydroxylation pattern in the B-ring of the flavonoid structure may be an

285 important determinant for the inhibitory action on enzyme activity. Sim et al. (2007) studied the  
286 structure-activity relationship of several flavonoids on MMP-1 gene expression in UV-A irradiated  
287 human dermal fibroblasts and demonstrated that the inhibitory effect at both protein and mRNA  
288 level, became stronger with increasing number of OH groups on the B-ring. Thus, the two hydroxyl  
289 groups present in the B ring of THFL may account for the inhibitory activity of those fractions  
290 enriched in this flavanone.

291 Fraction F5, containing CA and flavonol glycosides, showed a higher inhibitory action on  
292 collagenase than the total extract. This can be attributed to CA more than the glycoside molecules.  
293 Indeed, pure CA was tested on the enzyme activity and an  $IC_{50}$  value very close to that of the total  
294 extract was obtained (fig. 4A). The positive control EGCG yielded an  $IC_{50}$  value of 9.45  $\mu$ M.

295 To investigate the mechanism of enzyme inhibition, a Lineweaver-Burk plot was built by  
296 following the kinetics of collagenase in the absence and in the presence of *H. hircinum* extract. A  
297 60% decrease in  $V_{max}$  occurred when the extract was added, while the  $K_m$  value remained  
298 unchanged (Fig. 5), indicating that a non-competitive inhibitory mechanism was involved. This  
299 suggests that components of the extract may interact with sites different from the active site of the  
300 enzyme, an important aspect to consider when examining the potential of this plant as source of  
301 new anticollagenase agents. Indeed, results obtained by means of both computer simulation and  
302 experimental design by Westley and Westley (1996) indicated that competitive inhibitors are likely  
303 to be an inappropriate basis for design of potential therapeutic agents, due to the difficulty in  
304 providing a long-term inhibition, while the uncompetitive mechanism is much more likely to  
305 succeed in this.

#### 306 4. Conclusions

307 Present results indicate that *Hypericum hircinum* L. extracts show a rather strong antioxidant  
308 activity, which is mainly due to its phenolic compounds. Moreover, both the ethanolic extract and  
309 fractions containing quercetin, caffeoylquinic acids and 5,7,3',5'-tetrahydroxyflavanone, a

310 compound recently identified in this plant, were able to inhibit MMP1 enzyme activity through a  
311 non-competitive mechanism. This inhibitory action on MMP activity can explain, at least in part, its  
312 ethnobotanical uses. Based on these results, we suggest *H. hircinum* as a promising source for new  
313 anti-collagenase agents. In view of the importance that the maintenance of collagen structure has in  
314 preventing the skin ageing and photo-ageing processes, these molecules can enter as active  
315 ingredients in wrinkle-care cosmetics..

316 **Acknowledgements:** This research was supported by the FARB Basic Research Program (Grants  
317 for Basic Research, 2012; project No. FFBO123113) of the University of Bologna to F. P.

318

## 319 **References**

320 Araniti, F., Sorgonà, A., Lupini, A., Abenavoli, M.R., 2012. Screening of mediterranean wild plant  
321 species for allelopathic activity and their use as bio-herbicides. *Allelopath. J.* 29, 107-124.

322 Atzei, A.D., 2003. *Le piante nella tradizione popolare della Sardegna*, First ed. Delfino C. Sassari.

323 Ballero, M., Floris, R., Poli, F., 1997. Le piante utilizzate nella medicina popolare nel territorio di  
324 Laconi (Sardegna Centrale). *Boll. Soc. Sarda. Sci. Nat.* 31, 207-229.

325 Barbagallo, C., Chisari, G., 1987. Antimicrobial activity of three *Hypericum* species. *Fitoterapia* 58,  
326 175-180.

327 Belvisi, M.G., Bottomley, K.M., 2003. The role of matrix metalloproteinases (MMPs) in the  
328 pathophysiology of chronic obstructive pulmonary disease (COPD): a therapeutic role for  
329 inhibitors of MMPs. *Inflamm. Res.* 52, 95-100.

330 Berker, K.I., Glüçü, K., Demirata, B., Apak, R., 2010. A novel antioxidant assay of ferric reducing  
331 capacity measurement using ferrozine as the colour forming complexation reagent. *Anal.*  
332 *Methods* 2, 1770–1778.

333 Bochov, D.V., Sysolyatin, S.V., Kalashnikov, A.I., Surmacheva, I. A., 2012. Shikimic acid:  
334 review of its analytical, isolation, and purification techniques from plant and microbial sources.  
335 J. Chem. Biol. 5, 5–17.

336 Butterweck, V., 2003. Mechanism of action of ‘St John’s wort’ in depression: what is known? CNS  
337 Drugs 17, 539-562.

338 Cecchini, C., Cresci, A., Coman, M.M., Ricciutelli, M., Sagratini, G., Vittori, S., Lucarini, D.,  
339 Maggi, F., 2007. Antimicrobial activity of seven *Hypericum* entities from central Italy. Planta  
340 Med. 73, 564-566.

341 Chimenti, F., Cottiglia, F., Bonsignore, L., Casu, L., Casu, M., Floris, C, Secci, D., Bolasco, A.,  
342 Chimenti, P., Granese, A., Befani, O., Turini, P., Alcaro, S., Ortuso, F., Trombetta, G., Loizzo,  
343 A., Guarino, I., 2006. Quercetin as the active principle of *Hypericum hircinum* exerts a selective  
344 inhibitory activity against MAO-A: extraction, biological analysis, and computational study. J.  
345 Nat. Prod. 69, 945-949.

346 Di Pompo, G., Poli, F., Mandrone, M., Lorenzi, B., Roncuzzi, L., Baldini, N., Granchi, D., 2014.  
347 Comparative in vitro evaluation of the antiresorptive activity residing in four Ayurvedic  
348 medicinal plants. *Hemidesmus indicus* emerges for its potential in the treatment of bone loss  
349 diseases. J. Ethnopharmacol. 154, 462-470.

350 Elliott, S., Cawston, T., 2001. The clinical potential of matrix metalloproteinase inhibitors in the  
351 rheumatic disorders. *Drugs & Aging* 18, 87-99.

352 Ernst, E., Izzo, A.A., 2003. The clinical pharmacology of *Hypericum perforatum*. In: Ernst, E.  
353 (Eds.), *Hypericum: The Genus Hypericum*. Taylor and Francis, New York, pp. 155–172.

354 Esposito, F., Sanna, C., Del Vecchio, C., Cannas, V., Venditti, A., Corona, A., Bianco, A., Serrilli,  
355 A.M., Guarcini, L., Parolin, C., Ballero, M., Tramontano, E., 2013. *Hypericum hircinum* L.

356 components as new single molecule inhibitors of both HIV-1 reverse transcriptase-associated  
357 DNA polymerase and ribonuclease H activities. *Pathogens and Dis.* 68, 116-124.

358 Fu, X., Kassim, S.Y., Parks, W.C., Heinecke, J.W., 2001. Hypochlorous acid oxygenates the  
359 cysteine switch domain of pro-matrilysin (MMP-7). *J. Biol. Chem.* 276, 41279-41287.

360 Hashmi, M. A., Khan, A., Ayub, K., Farooq, U., 2014. Spectroscopic and density functional theory  
361 studies of 5,7,3',5'-tetrahydroxyflavanone from the leaves of *Olea ferruginea*. *Spectrochim.*  
362 *Acta Mol. Biomol. Spectros.* 128, 225–230.

363 Hertog, M.G.L., Hollman, P.C.H., Kahn, M.B., 1992. Content of potentially anticarcinogenic  
364 flavonoids of 28 vegetables and 9 fruits commonly consumed in the Netherlands. *J. Agric. Food*  
365 *Chem.* 40, 2379-2383.

366 Lee, I., Bae, J., Kim, T., Kwon, O. J., Kim, T.H., 2011. Polyphenolic constituents from the aerial  
367 parts of *Thymus quinquecostatus* var. *japonica* collected on ulleung Island. *J. Korean Soc.*  
368 *Appl. Biol. Chem.* 54, 811- 816.

369 Madhan B., Krishnamoorthy G., Rao J.R., Nair B.U., 2007. Role of green tea polyphenols in the  
370 inhibition of collagenolytic activity by collagenase. *Int. J. Biol. Macromolec.* 41, 16-22.

371 Maggi, F., Cecchini, C., Cresci, A., Coman, M.M., Tirillini, B., Sagratini, G., Papa, F., Vittori, S.,  
372 2010a. Chemical composition and antimicrobial activity of *Hypericum hircinum* L. subsp. majus  
373 essential oil. *Chem. Nat. Compounds* 46, 125-129.

374 Maggi, F., Tirillini, B., Vittori, S., Sagratini, G., Papa, F., 2010b. Chemical Composition and  
375 Seasonal Variation of *Hypericum hircinum* L. subsp. majus (Aiton) N. Robson essential oil. *J.*  
376 *Essent. Oil Res.* 22, 434-443.

377 Marandino, A., De Martino, L., Mancini, E., Milella, L., De Feo, V., 2011. Chemical composition  
378 and possible in vitro antigermination activity of three *Hypericum* essential oils. *Nat. Prod.*  
379 *Commun.* 6, 1735-1738.

380 Nessa, F., Ismail, Z., Mohamed, N., Haris, M.R.H.M., 2004. Free radical-scavenging activity of  
381 organic extracts and of pure flavonoids of *Blumea balsamifera* DC leale. Food Chem. 88, 243–  
382 252.

383 Pieroni, A, Quave, C.L, Santoro, R.F., 2004. Folk pharmaceutical knowledge in the territory of the  
384 Dolomiti Lucane, inland southern Italy. J. Ethnopharmacol. 95, 373-384.

385 Pilepić, K.H., Males, Z., 2013. Quantitative analysis of polyphenols in eighteen *Hypericum* taxa.  
386 Periodicum Biologorum 3, 459-462.

387 Pistelli, L., Bertoli, U.A., Zucconelli, S., Morelli, I., Panizzi, L., Menichini, F., 2000. Antimicrobial  
388 activity of crude extracts and pure compounds of *Hypericum hircinum*. Fitoterapia 71, S138-  
389 S140.

390 Raffetto, J.D., Khalil, R.A., 2008. Matrix metalloproteinases and their inhibitors in vascular  
391 remodeling and vascular disease. Biochem. Pharm. 75, 346–359.

392 Raghu Chandrashekhar, H., Venkatesh, P., Arumugam, M., Vijayan, P., 2009. Estimation of total  
393 phenols with special emphasis to antioxidant potentials of few *Hypericum* species.  
394 Pharmacologyonline 1, 680-687.

395 Rahman, I., MacNee, W., 1996. Role of oxidants/antioxidants in smoking-induced lung diseases.  
396 Free Radic. Biol. and Med. 21, 669-681.

397 Rodriguez-Landa, J.F., Contreras, C.M., 2003. A review of clinical and experimental observations  
398 about antidepressant actions and side effects produced by *Hypericum perforatum* extracts.  
399 Phytomed. 10, 688-699.

400 Schultz, G., Mozingo, D., Romanelli, M., Claxton, K., 2005. Wound healing and TIME; new  
401 concepts and scientific applications. Wound Repair Regen. 13, S1-S11.



402 Schütz, K., Kammerer, D., Carle, R., Schieber, A., 2004. Identification and quantification of  
403 caffeoylquinic acids and flavonoids from Artichoke (*Cynara scolymus* L.) heads, juice, and  
404 pomace by HPLC-DAD-ESI/MS. *J. Agric. Food Chem.* 52, 4090-4096.

405 Shah, S., Mohan M., Kasture, S., Ballero, M., Maxia, A., Sanna C., 2013. Protective effect of  
406 *Hypericum hircinum* on doxorubicin-induced cardiotoxicity in rats. *Nat. Prod. Res.* 27, 1502-  
407 1507.

408 Sin, B.Y., Kim H. P., 2005. Inhibition of Collagenase by Naturally-Occurring Flavonoids. *Arch.*  
409 *Pharmacol Res.* 10, 1152-1155.

410 Vaalamo, M., Weckroth, M., Puolakkainen, P., Kere, J., Saarinen, P., Lauharanta, J., Saarialho-  
411 Kere, U., 1996. Patterns of matrix metalloproteinase and TIMP-1 expression in chronic and  
412 normally healing human cutaneous wounds. *Br. J. Dermatol.* 135, 52-59.

413 Van Wart, H.E., Steinbrink, D.R., 1981. A continuous spectrophotometric assay for *Clostridium*  
414 *histoliticum* collagenase. *Anal. Biochem.* 113, 356-365.

415 Venditti, A., Mandrone, M., Serrilli, A.M., Bianco, A., Iannello, C., Poli, F., Antognoni, F., 2013.  
416 Dihydroasparagusic acid: antioxidant and tyrosinase inhibitory activities and improved synthesis.  
417 *J. Agric. Food Chem.* 61, 6848-6855.

418

419 **Figure legends**

420

421 **Fig. 1** Antioxidant activity, assayed by the DPPH and ABTS tests, of *H. hircinum* L. ethanolic  
422 extract and the six fractions (A), and of pure standard compounds (B). Data are expressed as IC<sub>50</sub>  
423 (μg/mL in A and μM in B). Asterisks indicate significant differences within the same assay at  
424  $P<0.01$  (\*\*) and  $P<0.001$  (\*\*\*) compared to the total extract (A) and Tr (B).


425 **Fig. 2** Fe<sup>3+</sup> reducing potential of *H. hircinum* ethanolic extract, fractions and pure compounds  
426 determined by the FRAP-FZ method. Results obtained for the extract and fractions are expressed as  
427 TAC units (A), while those for standard compounds are expressed as TEAC (B, insert). Asterisks  
428 indicate significant differences at  $P<0.05$  (\*),  $P<0.01$  (\*\*) and  $P<0.001$  (\*\*\*) compared to the total  
429 extract (A) and Tr (B)..

430 **Fig. 3** Inhibition of *in vitro* collagenase activity by *H. hircinum* L. ethanolic extract and fractions.  
431 A: IC<sub>50</sub> values of total extract and fractions giving a  $\geq 30\%$  inhibition of enzyme activity at a fixed  
432 concentration of 60 μg/mL. (B): Percentage of inhibition of the six fractions shown in decreasing  
433 order. Different letters indicate statistically significant differences at  $P<0.05$ .

434 **Fig. 4.** Inhibition of *in vitro* collagenase activity by *H. hircinum* ethanolic extract (A), CA (B) and  
435 EGCG (C). The enzyme assay was performed using 2 mM FALGPA as substrate. The IC<sub>50</sub> value  
436 for crude extract was calculated from the logarithmic curve  $y=a \ln(x)+b$ , where  $a=40.44$  and  $b=-$   
437  $121.7$  and  $R^2=0.989$ . The IC<sub>50</sub> value for CA was calculated by the linear regression curve  $y=a x +b$ ,  
438 where  $a=0.5684x$ ;  $b=27.956$  and  $R^2=0.997$ . The IC<sub>50</sub> value for EGCG was calculated from the  
439 logarithmic curve  $y=a \ln(x)+b$ , where  $a=20.523$ ,  $b=2.779$  and  $R^2=0.981$ .

440 **Fig. 5.** Lineaweaver-Burk plot of collagenase and FALGPA without (◆, CTR) and with (■) 156  
441 μg/mL of *H. hircinum* L. ethanolic extract. Kinetic parameters were calculated from the linear  
442 regression curves  $y=ax+c$ , where  $a=2.6676$ ;  $c=6.4377$  and  $R^2=0.999$  for ◆, while  $a=4.9275$ ;  
443  $c=10.279$ ;  $R^2=0.996$  for ■.

444 **Fig.1**  
445




446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456

457

458

459 **Fig. 2**




460

461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484


485  
486

**Fig. 3.**




487  
488  
489

**Fig. 4**



490  
491

**Fig. 5**



492  
493  
494  
495  
496  
497  
498  
499  
500

**Table 1.** Antioxidant activities measured by ABTS, DPPH, and FRAP-FZ. Values are expressed as IC<sub>50</sub> (μg/mL or μM for pure compounds), TAC (mmol TE/g extract) or TEAC (Trolox equivalent antioxidant capacity). Data are the mean of three independent experiments. Different letters, within the same assay, indicate significant differences (P < 0.01) among IC<sub>50</sub> values.

		DPPH	ABTS	FRAP-FZ
<i>H. hircinum</i> extract	IC <sub>50</sub> (μg/mL)	10.13±0.73 <sup>a</sup>	10.19±0.82 <sup>A</sup>	46.39±2.57 <sup>a</sup>
	TAC	1.32±0.16	1.99±0.17	0.91±0.08
CA	IC <sub>50</sub> (μg/mL)	1.06±0.22 <sup>b</sup>	0.83±0.02 <sup>B</sup>	38.47±1.33 <sup>b</sup>
	IC <sub>50</sub> (μM)	3.01±0.64	2.33±0.07	
	TAC	12.89±3.05	24.52±0.76	
	TEAC	4.57±1.07	6.92±1.48	1.10±0.08
Q	IC <sub>50</sub> (μg/mL)	0.20±0.01 <sup>c</sup>	0.92±0.03 <sup>C</sup>	15.88±0.32 <sup>c</sup>
	IC <sub>50</sub> (μM)	0.58±0.02	2.72±0.09	
	TAC	68.09±7.19	21.95±0.77	
	TEAC	23.02±2.40	7.43±0.26	2.66±0.16
SA	IC <sub>50</sub> (μg/mL)	> 100 <sup>d</sup>	> 100 <sup>D</sup>	423±12. <sup>d</sup>
	IC <sub>50</sub> (μM)	> 50	> 50	
	TAC	< 1	< 1	
	TEAC	< 5	< 5	0.10 ± 0.01
Tr	IC <sub>50</sub> (μg/mL)	3.35±0.34 <sup>e</sup>	5.07±0.03 <sup>E</sup>	*42.33±2.5 <sup>a</sup>
	IC <sub>50</sub> (μM)	13.38±1.34	20.28±0.12	

501